DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease

Information source: Nanfang Hospital of Southern Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Nonalcoholic Fatty Liver Disease (NAFLD)

Intervention: Perindopril (Drug); Telmisartan (Drug); Amlodipine (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Nanfang Hospital of Southern Medical University

Official(s) and/or principal investigator(s):
Side Liu, MD,PhD, Principal Investigator, Affiliation: Department of Gastroenterology, Nanfang Hospital, Southern Medical University

Overall contact:
Side Liu, MD,PhD, Phone: +86 020 61641537, Email: liuside2011@163.com

Summary

The aim of this current study was to assess the therapeutic effects of perindopril and telmisartan for hypertensive patients with NAFLD and make comparison between the therapeutic effects of these two kind of drugs. This study is a randomized parallel control clinical trial which would be carried out in Nanfang Hospital, Southern Medical University. About one hundred and eighty patients would be randomly assigned to perindopril,telmisartan and amlodipine three groups.

Clinical Details

Official title: Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Cap value of FibroScan (dB/m)

Secondary outcome:

Angiotensin II

IL-18,IL-1β

aminotransferase

lipids

HOMA-IR

computed tomography value of liver

Detailed description: Inclusion criteria: 18-70 years old patients who were diagnosed with mild-moderate hypertension and NAFLD; The patients did not take ACEIs or ARBs drugs six weeks before the inclusion; Patients agreed to participate in the trial and signed the informed consent. Exclusion criteria: There are no coexisting causes for chronic liver disease, such as viral, alcoholic,drug-induced and autoimmune liver diseases; Patients with diabetes mellitus; Patients with serious primary diseases; Patients with mental disorder or can not take the medicine regularly; Pregnancy and nursing mothers; Allergic constitution or intolerance to ACEIs or ARBs drugs. Outcome measures include Cap value of FibroScan,angiotensin II,IL-18,IL-1β,aminotransferase,lipids and HOMA-IR.

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- 18-70 years old patients who were diagnosed with mild-moderate hypertension and

NAFLD;

- The patients did not take ACEIs or ARBs drugs six weeks before the inclusion;

Patients agreed to participate in the trial and signed the informed consent. Exclusion Criteria:

- There are no coexisting causes for chronic liver disease, such as viral,

alcoholic,drug-induced and autoimmune liver diseases;

- Patients with diabetes mellitus; Patients with serious primary diseases; Patients

with mental disorder or can not take the medicine regularly;

- Pregnancy and nursing mothers;

- Allergic constitution or intolerance to ACEIs or ARBs drugs.

Locations and Contacts

Side Liu, MD,PhD, Phone: +86 020 61641537, Email: liuside2011@163.com

Nanfang Hospital, Southern Medical University, GuangZhou, Guangdong 510515, China; Recruiting
Yue Li, MD, Phone: +86-15975537291, Email: liyue_1989919@126.com
Side Liu, MD.PhD, Principal Investigator
Yue Li, MD, Sub-Investigator
Xu Li, MD, Sub-Investigator
Zelong Han, MD, Sub-Investigator
Wen Xu, MM, Sub-Investigator
Yubin Guo, MM, Sub-Investigator
Feng Xiong, MD, Sub-Investigator
Additional Information

Starting date: August 2014
Last updated: August 8, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017